Targets › ACHE
21 programs from 19 companies in 24 trials: 13 Phase 2, 5 Phase 1, 4 Phase 4, 2 Phase 3; Neurology, Cardiovascular, Other; next expected readout Dec 2026.
Hydrolyzes rapidly the acetylcholine neurotransmitter released into the synaptic cleft allowing to terminate the signal transduction at the neuromuscular junction. Role in neuronal apoptosis. (UniProt, P22303)
Open in Phaseline: the race on ACHE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Wanbangde Pharmaceutical Group | Huperzine A Controlled-Release Tablets Acetylcholinesterase inhibitor | ACHE | Phase 4 | Cognitive Impairment After Brain Injury; Alzheimer Dementia | Dec 2026 |
| Alpha Cognition | Benzgalantamine Acetylcholinesterase inhibitor | ACHE | Phase 4 | Alzheimer Disease | Apr 2027 |
| Virginia Commonwealth University | Galantamine Acetylcholinesterase inhibitor | ACHE | Phase 4 | Dementia With Lewy Bodies | Nov 2029 |
| University of Sao Paulo | Donepezil Acetylcholinesterase inhibitor | ACHE | Phase 4 | Tinnitus | – |
| Assistance Publique - Hôpitaux de Paris | Donepezil Acetylcholinesterase inhibitor | ACHE | Phase 3 | Alzheimer Disease, Early Onset | – |
| James J. Peters Veterans Affairs Medical Center | Neostigmine Acetylcholinesterase inhibitor | ACHE | Phase 3 | Spinal Cord Injuries | – |
| University of Vermont Medical Center | Pyridostigmine Bromide Acetylcholinesterase inhibitor | ACHE | Phase 2 | Parkinson Disease | Dec 2026 |
| Mayo Clinic | pyridostigmine Acetylcholinesterase inhibitor | ACHE | Phase 2 | Postural Tachycardia Syndrome | Feb 2027 |
| Assiut University | Neostigmine Acetylcholinesterase inhibitor | ACHE | Phase 2 | Postdural Puncture Headache (PDPH) | Mar 2027 |
| Northwell Health | Galantamine Hydrobromide Acetylcholinesterase inhibitor | ACHE | Phase 2 | Spinal Cord Injury | Aug 2027 |
| Supernus Pharmaceuticals | Huperzine A (SPN-817) Acetylcholinesterase inhibitor | ACHE | Phase 2 | Focal Onset Seizures; Epilepsy | Aug 2027 |
| Duke University | Donepezil Acetylcholinesterase inhibitor | ACHE | Phase 2 | Osteoporosis | Sep 2027 |
| Brigham and Women's Hospital | Pyridostigmine Acetylcholinesterase inhibitor | ACHE | Phase 2 | ME/CFS | Sep 2027 |
| Shanghai Yueyang Integrated Medicine Hospital | Galantamine Acetylcholinesterase inhibitor | ACHE | Phase 2 | Acute Ischemic Stroke AIS | Sep 2028 |
| Washington University School of Medicine | Rivastigmine Cholinesterases; ACHE & BCHE inhibitor | BCHE, ACHE | Phase 2 | Anticholinergic Toxicity | Nov 2028 |
| VA Connecticut Healthcare System | Donepezil Acetylcholinesterase inhibitor | ACHE | Phase 2 | Alcohol Use Disorder | – |
| Stefan Holubar MD MS FACS, FASCRS | Pyridostigmine Bromide Acetylcholinesterase inhibitor | ACHE | Phase 2 | Postoperative Ileus | – |
| Supernus Pharmaceuticals | BIS-001-ER acetylcholinesterase inhibitor | ACHE | Phase 1 | Focal Impaired Awareness Seizures | Dec 2026 |
| Vanderbilt University Medical Center | Galantamine Acetylcholinesterase inhibitor | ACHE | Phase 1 | Endothelial Dysfunction; Postural Tachycardia Syndrome | May 2027 |
| Vanderbilt University Medical Center | Pyridostigmine Acetylcholinesterase inhibitor | ACHE | Phase 1 | Postural Tachycardia Syndrome | Jun 2027 |
| Inventage Lab. | IVL3003 Donepezil long-acting injection | ACHE | Phase 1 | Alzheimer Disease | – |
Postural Tachycardia Syndrome (3) Alzheimer Disease (2) Postdural Puncture Headache (PDPH) (1) Endothelial Dysfunction (1) Osteoporosis (1) Alcohol Use Disorder (1) ME/CFS (1) Cognitive Impairment After Brain Injury (1) Alzheimer Dementia (1) Anticholinergic Toxicity (1) Spinal Cord Injuries (1) Postoperative Ileus (1)
small molecule (14), protein or peptide (3), mixed (2), antibody (1)
Vanderbilt University Medical Center (2) Supernus Pharmaceuticals (2) Mayo Clinic (1) Assiut University (1) Duke University (1) VA Connecticut Healthcare System (1) Brigham and Women's Hospital (1) Wanbangde Pharmaceutical Group (1) Washington University School of Medicine (1) James J. Peters Veterans Affairs Medical Center (1) Stefan Holubar MD MS FACS, FASCRS (1) Shanghai Yueyang Integrated Medicine Hospital (1) Inventage Lab. (1) Northwell Health (1) University of Sao Paulo (1) Virginia Commonwealth University (1) Assistance Publique - Hôpitaux de Paris (1) Alpha Cognition (1) University of Vermont Medical Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.